Actinium Pharmaceuticals
ATNM
31 hedge funds and large institutions have $8.16M invested in Actinium Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 5 closing their positions.
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
59% more capital invested
Capital invested by funds: $5.14M → $8.16M (+$3.02M)
19% more funds holding
Funds holding: 26 → 31 (+5)
0.35% more ownership
Funds ownership: 0.24% → 0.59% (+0.35%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$3.21M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.78M |
| 3 |
SCM
Sio Capital Management
New York
|
+$1.16M |
| 4 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$749K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$549K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$110K |
| 2 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
-$58.5K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$22K |
| 4 |
Renaissance Technologies
New York
|
-$14K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SXL
26
Summit X LLC
Chesterfield,
Missouri
| $7K | – | – | – |
|
|
AG
27
Advisor Group
Phoenix,
Arizona
| $2K | – | – | – |
|
28
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | -$1.43K | -65 | -44% |
|
29
Bank of Montreal
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
30
Bank of America
Charlotte,
North Carolina
| $1K | +$702 | +32 | New |
|
|
VFA
31
Valeo Financial Advisors
Carmel,
Indiana
| $1K | +$1.1K | +50 | New |
|
|
32
Group One Trading
Chicago,
Illinois
| – | -$22K | -602 | Closed |
|
|
33
Renaissance Technologies
New York
| – | -$14K | -382 | Closed |
|
|
34
Creative Planning
Overland Park,
Kansas
| – | -$5K | -131 | Closed |
|
|
AIM
35
Acrospire Investment Management
Chicago,
Illinois
| – | -$2K | -63 | Closed |
|
|
MIM
36
Macroview Investment Management
Bethesda,
Maryland
| – | -$1K | -17 | Closed |
|
ATNM Hedge Fund Activity: Q3 2017 in Review
31 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q3 2017, worth a combined $8.16M — up 59% from $5.14M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ATNM positions and 5 closed out — a net gain of 6 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $3.21M. The largest seller was Bridgeway Capital Management, cutting an estimated $110K.
- 31 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q3 2017, up from 26 in Q2 2017.
- Funds reported $8.16M of Actinium Pharmaceuticals stock for Q3 2017, up 59% quarter-over-quarter.
- 11 funds opened new Actinium Pharmaceuticals positions in Q3 2017 and 5 closed out, a net change of +6 holders.
- The largest Actinium Pharmaceuticals buyer in Q3 2017 was Armistice Capital, an estimated $3.21M added.
- The largest Actinium Pharmaceuticals seller in Q3 2017 was Bridgeway Capital Management, an estimated $110K sold.
Based on aggregated 13F filings for Q3 2017.